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 Pain is one of most common and difficult symptoms 
in cancer; thus, its management is extremely important
［1］. It is experienced by 20%-50% of patients with 
cancer at diagnosis and by up to 60%-90% in those with 
cancer at an advanced stage［2］.
 Nonsteroidal anti-inflammatory drugs （NSAIDs） 
are recommended by the World Health Organization for 
the treatment of cancer pain［3］. In Japan, loxoprofen 
is the most commonly used NSAID［4］. However, the 
appropriate type of NSAID for treating cancer pain is 
yet to be established［5］.
 Existing literature indicates that naproxen （750-
1,100 mg/day） is not superior to diclofenac （200 mg/
day）, indomethacin （150 mg/day）, or aspirin （2400 
mg/day）［6-8］. Additionally, in Japan, the maximum 
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Abstract
Nonsteroidal anti-inflammatory drugs （NSAIDs） are recommended by the World Health 
Organization for the treatment of cancer pain. In Japan, loxoprofen is the most commonly 
used drug among a variety of NSAIDs. However, our palliative care team （PCT） switched 
from loxoprofen to naproxen, a long-acting NSAID, for cancer pain. Consequently, our clinical 
impression was that the pain score was often improved. Therefore, we investigated whether 
switching from loxoprofen to naproxen reduced cancer pain.
A retrospective medical record survey was conducted. In a total of 119 inpatients who 
consulted the PCT from April 2018 to February 2019 in the Tokyo Medical University Hospital, 
10 cases were enrolled in this study. We first switched the prescribed NSAID loxoprofen to 
naproxen for these patients. Furthermore, the mean numerical rating scale （NRS） scores, body 
temperatures, opioid prescriptions, and numbers of rescue doses were recorded on the days 
before and after switching the drugs.
Consequently, the means of the NRS scores before and after switching the NSAIDs were 
3.50±1.62 （mean±SD） （range: 1.7-6.5） and 1.15±1.48 （0-3.67） （p＜0.001, using the paired 
t-test）, respectively.
Moreover, no statistical differences were noted on the other survey variables （p＞0.05）.
In conclusion, compared with loxoprofen, naproxen may be effective in reducing mild-to-
moderate cancer pain.
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dosages of naproxen and loxoprofen are 600 mg/day 
（Interview form of naproxen: https://www.mhlw.go.jp/
content/11121000/000342038.pdf） and 180 mg/day, 
respectively （Interview form of loxoprofen:https://
www.mhlw.go.jp/file/05-Shingikai-11121000-
Iyakushokuhinkyoku-Soumuka/0000065373.pdf）. 
However, no comparative studies between these two 
drugs, at the doses used in Japan, have been conducted 
with respect to treating cancer pain.
 Therefore, we conducted a retrospective survey to 
investigate the effectiveness of switching from 180 mg 
of loxoprofen to 600 mg of naproxen, in reducing cancer 
pain.
 In this study, we aimed to determine whether 600 
mg/day of naproxen decreases the mean numerical 
rating scale （NRS） scores in inpatients with cancer pain 
compared with the prescribed loxoprofen dosage of 180 
mg/day. The secondary aims were to investigate the 
needed rescue doses of opioids and body temperature 
after switching from loxoprofen to naproxen.
 The clinical records of 119 inpatients who consulted 
the palliative care team （PCT） for cancer pain at the 
Tokyo Medical University Hospital, Japan, from April 
2018 to February 2019 were retrospectively reviewed. 
Consequently, 10 of them who were prescribed 
loxoprofen and had this NSAID switched to naproxen 
by the PCT, because the PCT evaluated that switching 
NSAIDs was appropriate for mild-to-moderate pain, 
were enrolled. At the day of switching NSAIDs, 600 mg 
of naproxen were administered.
 The following demographic clinical data were 
collected: gender, age, cancer type, prescribed opioid, 
and pain site. In addition, the means of NRS （at least 
3 times a day）, number of rescue analgesics for pain 
relief, and body temperatures before and after switching 
from loxoprofen to naproxen were compared. Only the 
before and after days were selected because more factors 
（e.g., cancer growths, other drugs, physical conditions） 
can influence the NRS scores.
 The statistical analysis of data was performed using 
the paired t-test with Prism 4 for Macintosh. P values of
＜0.05 were considered statistically significant, and the 
results were expressed as the mean±standard deviation.
 Of the 10 inpatients who were enrolled in this study, 
80% were males （n＝8）, and 20% were females （n＝
2）, with their ages ranging from 49 to 85 years old. 
In addition, the diagnoses were as follows” cancers of 
the lung （n＝2）, esophagus （n＝1）, thyroid （n＝3）, 
pancreatic （n＝3）, and bile duct （cholangiocarcinoma） 
（n＝1）. Furthermore, the pain sites include the neck 
（owing to bone metastasis） （n＝3）, upper limb （owing 
to neuropathic pain） （n＝1）, chest （owing to bone 
metastasis） （n＝1）, abdomen （owing to visceral pain） 
（n＝4）, and back （owing to bone metastasis） （n＝1）. 
Seven patients using opioids were also observed: slow-
release oxycodone （10-20 mg/day） （n＝5）, morphine 
sulfate （20 mg/day） （n＝1）, and transdermal fentanyl 
（4 mg/day） （n ＝1）. Each rescue dose was set at 
10～20% of the daily opioid consumption, except for 
fentanyl buccal （100 microgram/time）. Additionally, 
there were 3 patients who were not using opioids. 
 The mean NRS score on the day before switching 
the NSAIDs （i.e., from loxoprofen ［180 mg/day］ to 
naproxen ［600 mg/day］） was 3.50±1.62 （range, 
1.7-6.5）, whereas that on the day after switching the 
NSAID was 1.15±1.48 （0-3.67） （p＜0.001）. （Fig. 
1） Further, the mean of the difference was 2.35 （95% 
confidence intervals, 1.64-3.07）.
 The numbers of rescue doses administered on the 
days before and after switching the NSAIDs were 2.3±
3.3 and 2.1±3.5/day （p＞0.05）, respectively. 
 The mean body temperatures on the days before and 
after switching the NSAIDs were 36.7±0.2 and 36.8±
Fig. 1　Mean NRS scores on the days before and after 
switching from loxoprofen to naproxen. The mean NRS 
scores before and after were 3.50±1.62 and 1.15±1.48 
（p＜0.001, using the paired t-test）, respectively.
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0.31 （p＞0.05） ℃, respectively.
 No adverse events of naproxen were noted during the 
period （e.g. acute drug allergic reaction, gastrointestinal 
disorder, and bleeding）.
 To the best of our knowledge, this is the first report 
describing the effectiveness of switching 180 mg/day 
of loxoprofen as the prescribed NSAID to 600 mg/
day of naproxen in reducing cancer pain. A statistically 
significant decrease in the group difference of the mean 
NRS scores was noted after switching from loxoprofen 
to naproxen （p＜0.001）. In addition, no significant 
difference in the number of rescue doses was found 
（p ＞0.05）. Therefore, these findings suggest that 
switching from loxoprofen to naproxen is effective in 
reducing any type of cancer pain.
 Although naproxen is often used for tumor fever
［9］, this study showed that no significant differences 
were noted in the body temperatures after switching the 
NSAID because the patients were afebrile.
 Clinically, loxoprofen is often prescribed because 
of its prodrug property that reduces gastrointestinal 
complications. In addition, its half-life （T1/2） is 2.2 h, 
whereas that of naproxen is 14 h. End-of-dose failure 
in opioids is well known; therefore, controlled-release 
opioids are recommended for sustained cancer pain 
management, except for breakthrough pain［10,11］. 
Therefore, our results suggest that NSAIDs with long 
half-lives are suitable for the reduction of cancer 
pain. Previous comparative studies of naproxen and 
other NSAIDs, which indicated that naproxen was not 
superior to other NSAIDs, were studied at the greater 
doses than that used in Japan, i.e., almost double doses 
（e.g., in Japan, 75 mg is administered for indometacin 
and dicrofenac）. There are no comparative studies of 
the differences of drug potency between loxoprofen 
and naproxen, especially at the doses used in Japan, 
therefore, the comparison of clinical doses we can use 
safely is important. 
 Our study has some limitations. First, in this study, 
a retrospective medical record survey was conducted. At 
the time of the PCT’s first action, biases may be present 
because the PCT evaluated that switching only NSAIDs 
was appropriate for mild-to-moderate pain （range of 
mean NRS scores: 1.7-6.5）. Thus, the finding may not 
be applicable to patients with severe cancer pain.
 Second, a comparison of this current study with one 
involving the switch of naproxen to loxoprofen has not 
yet been elucidated.
 In conclusion, naproxen may be effective in 
reducing mild-to-moderate cancer pain. However, 
further clinical trials are needed to confirm the result.
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